Japan Approves Groundbreaking Alzheimer’s Drug Leqembi, Offering Hope to Aging Population
Japan’s health ministry has given its approval for the use of the drug Leqembi, which is aimed at treating Alzheimer’s disease. This groundbreaking drug was developed through a joint effort between Japanese pharmaceutical company Eisai Co. and U.S. biotechnology firm Biogen Inc. It is a crucial development considering the rapidly aging population in Japan.
The authorization of Leqembi in Japan comes two months after it received the endorsement of the U.S. Food and Drug Administration. The drug specifically targets patients with mild dementia and other early-stage symptoms of Alzheimer’s disease. It has proven to be the first medication capable of modestly slowing down cognitive decline in these individuals.
Japanese Prime Minister Fumio Kishida expressed his enthusiasm for the approval of Leqembi, describing it as a significant breakthrough and stating that the treatment of dementia has now entered a new era. Recognizing the growing number of dementia patients and their families, Kishida has pledged to provide increased support and is set to launch a panel to discuss measures for creating a dementia-friendly society.
According to the health ministry, Japan’s elderly population is expected to see a rise in the number of dementia patients aged 65 and above from the current 6 million to 7 million by 2025. This highlights the urgency and importance of effective treatments for Alzheimer’s disease.
However, it should be noted that Leqembi does not work for everyone, and like other drugs targeting Alzheimer’s-associated brain plaques, it can have potentially dangerous side effects such as brain swelling and bleeding in rare cases.
To address these concerns, Eisai Co. has committed to conducting a post-marketing special use survey involving all patients who receive the drug. This will allow them to gather sufficient data and evaluate outcomes under the procedures set by the Japanese health ministry.
Leqembi is slated to be partially covered by health insurance and is expected to be available for clinical use by the end of this year. While the price has yet to be finalized, reports suggest that it may be expensive. Eisai, however, remains dedicated to delivering Leqembi as a new treatment option for those in need and their families. Haruo Naito, the CEO of Eisai, emphasized the company’s aim to make an impact on the pressing issues surrounding dementia in Japanese society through the availability of this drug.
With the approval of Leqembi, hopes are high that it will significantly contribute to the treatment of Alzheimer’s disease in Japan. The drug represents an important step forward in addressing the challenges faced by the country’s aging population. As further research and developments continue, the focus remains on ensuring the well-being and quality of life for those affected by this debilitating condition.
